Skip to content

Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer

Longitudinal Observational Study About the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03669952
Enrollment
464
Registered
2018-09-13
Start date
2010-01-01
Completion date
2015-12-31
Last updated
2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Outcome of Breast Cancer

Keywords

Breast cancer, Ductal carcinoma in situ, Invasive ductal carcinoma, Prognosis factors

Brief summary

A prospective observational longitudinal study of 464 patients was performed between 2010 and 2015. Patients with invasive ductal carcinoma (IDC) and ductal carcinoma in situ associated to invasive ductal carcinoma (DCIS +IDC) were included and analyzed.

Detailed description

Type of study: A prospective observational longitudinal study was performed on patients who had undergone curative surgery for primary invasive breast cancer between 2010 and 2015. The study was performed in a single breast pathology unit \[Alt Penedés hospital and Sant Camil hospital(GAP)\]. Only patients with a definitive histopathology-based diagnostic of ductal carcinoma were included. Patients diagnosed with metastasis were excluded. Patients with bilateral breast cancer were included as two independent study cases. Patients: Sample size calculation: 191. A total of 464 patients were included in the study. IDC was present in 221 patients (47.6%) and IDC + DCIS was present in 243 patients (52.4%). Data collected included clinical characteristics (age, laterality and clinical symptoms at the time of diagnostic), histopathological information (tumor size, tumor grade, hormone receptors, nodal status, HER-2 mutation (erb-b2 receptor tyrosine kinase 2), number of ki67, presence and percentage of DCIS, grade of DCIS, and surrogate subtype) and surgical procedure performed. Tumor histopathology and the number of lymph nodes involved were evaluated by routine hematoxylin-eosin (H&E) staining. The histological response to chemotherapy was assessed according to Miller-Payne criteria of grading (MPG) and Residual Disease in Breast and Nodes (RDBN). The percentage of DCIS and its grade (classified as low, intermediate or high) was measured by two independent pathologists. Statistical analysis: Quantitative data are shown as the median or mean of values and their variability is expressed as the range or standard deviation (SD), as specified for each analysis. Qualitative data are shown as absolute values or percentages. The incidence was used as a measure of frequency and the relative risk as a measure of association between independent groups. The study of the normality of quantitative variables was done applying the Kolmogorov-Smirnov or the Shapiro-Wilk tests, as indicated for each analysis. For significance assessment of quantitative data, unpaired Student's T-test or two-tailed Mann-Whitney U test was applied, as specified for each analysis. For significance assessment of qualitative data, Fisher's exact test or Chi-squared test was applied. For the analysis of more than two groups, one-way ANOVA and Tukey's range test for post hoc pairwise comparison of groups, or Kruskal-Wallis were used. Survival was analyzed with the Kaplan-Meier estimate and survival distributions compared with the Log-Rank test. Multivariate Cox proportional hazards regression model was used to simultaneously evaluate the effect of several factors on survival and mortality. Statistical analysis was performed using the software SPSS® (Statistical Package for the Social Sciences) version 21. The aim of the investigator's study is to compare the clinical and histopathological factors between patients with IDC or DCIS-associated IDC (IDC + DCIS) and find the prognostic factors associated to recurrence and mortality in each group.

Interventions

OTHERNone intervention

No interventions are realized, only observational study

Sponsors

Omphis Foundation
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with invasive ductal carcinoma of the breast * Patients who received surgery for primary invasive breast cancer between 2010 and 2015

Exclusion criteria

* Patients with metastasis at the diagnostic

Design outcomes

Primary

MeasureTime frameDescription
RecurrencePatients included between 2010 and 2015 will be follow up til January of 2018 with a mean follow up of 51.43 monthsNeoplasm metastasis, either local or distant recurrence of the invasive ductal carcinoma

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026